Your session is about to expire
← Back to Search
18F-Fluciclovine PET/MRI for Prostate Cancer
N/A
Waitlist Available
Led By Devaki S Surasi
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights
Study Summary
This trial will compare how well two different diagnostic tools work in finding signs of cancer in the pelvis.
Who is the study for?
This trial is for men over 18 with prostate cancer that's come back after radiation. They must understand and agree to the study rules, and have a rising PSA level suggesting cancer return. It's not for those who can't have MRIs, are extremely claustrophobic, allergic to MRI dyes, or if other health issues could mess up the study.Check my eligibility
What is being tested?
The study tests how well a special imaging agent called 18F-fluciclovine works during PET scans combined with MRIs using a machine that does both at once. This might help see where prostate cancer has returned more clearly.See study design
What are the potential side effects?
Possible side effects from the imaging agent include irritation at injection site or allergic reactions. The MRI may cause discomfort for those with claustrophobia despite not being eligible if it's extreme.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, an average of 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
To assess the diagnostic performance of 18F- Fluciclovine pelvic PET/MRI to that of pelvic mpMRI
Trial Design
1Treatment groups
Experimental Treatment
Group I: 18F-ACBCExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
18F-fluciclovine
2021
Completed Early Phase 1
~40
Find a Location
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
2,967 Previous Clinical Trials
1,804,802 Total Patients Enrolled
95 Trials studying Prostate Cancer
29,740 Patients Enrolled for Prostate Cancer
Devaki S SurasiPrincipal InvestigatorM.D. Anderson Cancer Center
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a medical condition that may affect the accuracy of the study results or prevent you from meeting the study requirements.You have a severe fear of enclosed spaces (claustrophobia).You had an allergic reaction to an MRI contrast agent in the past.
Research Study Groups:
This trial has the following groups:- Group 1: 18F-ACBC
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any vacancies in this clinical trial for participants?
"Data found on clinicaltrials.gov indicates that patient recruitment is inactive for this trial; its initial posting was made September 30th 2022 and it has not been updated since February 14th of the same year. Notwithstanding, there are over 1300 medical studies currently recruiting enrollees."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger